DZL researchers at Helmholtz Munich and their collaborators developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and allows learning about lung biology...
DZL scientist Dr. Bilal Alashkar Alhamwe is researching how exposure to the bacterium Acinetobacter lwoffii can protect us from chronic inflammatory diseases such as asthma.
Asthma: Results from the ALLIANCE registry could help detect inflammation in the small airways more easily in the future.
The DZL supports a position paper of the German Respiratory Society (DGP e. V.), which advises against using e-cigarettes. They are not a suitable aid for quitting smoking.
Breath analysis by mass spectroscopic methods could enable innovative diagnostics.
Further funding of clinical studies by the DZL in 2022. Two studies were successful in this year's application round.
Allergy or no allergy? New basophil activation test complements spectrum of routine diagnostics.
The DZL Annual Report 2020 has been published in German and English and is now available from the Media Center.
Specific immune cells are less abundant in children with allergic asthma than in healthy individuals.
The "Förderpreis für Allergen Immuntherapie" awarded by the German Society for Allergology and Clinical Immunology (DGAKI), goes this year to the DZL scientist Dr. Ulrich Zißler.
Researchers of DZL analyzed lung collagen degradation and found a way to predict the course of an antibody therapy with omalizumab.
COVID-19 disease severity is determined by the individual patient’s immune response. The precise mechanisms taking place inside the lungs and blood during the early phase of the disease remain unclear.
